ImpediMed Limited announced that the PREVENT trial is now complete and the study investigators have commenced work on a manuscript ahead of its planned submission by the end of February 2021. The Principal Investigator, Sheila H. Ridner, PhD, RN, FAAN, Professor of Nursing at Vanderbilt University School of Nursing, has communicated the following to the Company: All PREVENT trial patients have now completed their follow-up visits; No patients are still undergoing treatment; The 10 participating sites are closed, and all data is currently being compiled; The investigators expect to have the paper finalised and submitted for initial journal review by the end of February 2021. The PREVENT trial is a seminal study, the largest randomised controlled trial to be conducted on patients at-risk of lymphoedema. The study enrolled >1100 patients across 10 trial sites in the US and Australia, involving 13 hospitals. Of these, 3 of the 9 US sites are National Comprehensive Cancer Network (NCCN) Member Institutions. The trial was conducted over six and a half years and patients were followed for up to 3 years, with the primary aim to determine if subclinical detection of extracellular fluid accumulation via bioimpedance spectroscopy, and subsequent early intervention, reduces the rate of lymphoedema progression relative to the rate when using tape measurements.